AKBA Akebia Therapeutics, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
AKBA Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$1.36
Analyst Target
$5.4
+297.1%
Upside
52W High
$4.08
52W Low
$1.3
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$360.9M
P/E
N/A
ROE
N/A
Profit margin
-7.1%
Debt/Equity
4.78
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
The Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, while the Altman Z-Score is unavailable, limiting bankruptcy risk assessment. Despite a high revenue growth rate of 57% YoY and strong analyst recommendation of 'strong_buy', the company remains unprofitable with a negative profit margin of -7.07% and elevated Debt/Equity of 4.78, raising sustainability concerns. Valuation metrics such as a Price/Book of 8.66 and Forward P/E of 8.00 suggest pricing ahead of fundamentals, while insider sentiment is weak at 40/100. The stock trades significantly below the $5.40 analyst target, implying upside potential if execution improves.
Key Strengths
Exceptional year-over-year revenue growth of 57.00%, outpacing sector average of 62.37% and signaling strong commercial traction
High gross margin of 83.32%, reflecting pricing power and low cost of goods, typical of specialty pharma business models
Recent earnings surprises are strongly positive, with 3 out of last 4 quarters beating estimates and an average surprise of 120.58%
Current Ratio of 1.94 and Quick Ratio of 1.74 indicate sufficient short-term liquidity to meet obligations
Analyst consensus is 'strong_buy' with a $5.40 target price, implying ~297% upside from current levels
Key Risks
Piotroski F-Score of 4/9 indicates borderline financial health, with risk of deterioration if profitability or leverage worsens
Debt/Equity ratio of 4.78 is significantly above sector average of 2.70, increasing financial risk and refinancing pressure
Profit margin is negative at -7.07%, and ROE is unavailable, suggesting ongoing unprofitability and weak return generation
Insider sentiment is weak at 40/100, indicating lack of confidence from company insiders despite bullish analyst views
Technical trend score of 0/100 signals strong bearish momentum, with 1-year return of -43.1% and 6-month return of -61.8%
AI Fair Value Estimate
Based on comprehensive analysis
$5.4
+297.1% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
42
Moderate
45
75
50
40
0
AI Verdict
Cautiously optimistic with significant execution and financial risk
Key drivers: High revenue growth and analyst optimism, Improving earnings trends and strong gross margins, Elevated leverage and weak profitability, Bearish technicals and weak insider sentiment
Confidence
70%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 8.00 is low relative to sector average P/E of 203.10
Watchpoints
- Price/Book of 8.66 is high for a company with negative earnings and weak ROE
- No Graham Number available, indicating lack of defensive value support
Future
75/100
Ref Growth rates
Positives
- Revenue Growth (YoY) of 57.00% is robust
- Most Recent Q/Q EPS Growth of +120.0% and YoY EPS Growth of +125.0% signal accelerating profitability
Watchpoints
- Earnings Growth (YoY) is listed as N/A, indicating inconsistency or non-GAAP reporting
Past
50/100
Ref Historical trends
Positives
- Recent quarters show improved earnings performance with multiple large positive surprises
Watchpoints
- Historical EPS surprises are volatile, with several large negative misses prior to 2023
- Long-term price performance is weak: 5Y change of -63.3%
Health
40/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current and Quick Ratios above 1.7 indicate short-term liquidity adequacy
Watchpoints
- Piotroski F-Score of 4/9 indicates only moderate financial stability
- Debt/Equity of 4.78 is dangerously high, increasing risk of distress
- Altman Z-Score is unavailable, limiting distress risk assessment
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength is 0/100
- No dividend yield or payout history, typical for unprofitable biotech firms
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.36
Analyst Target
$5.4
Upside/Downside
+297.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AKBA and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
Primary
|
-63.3% | +88.4% | -43.1% | -61.8% | -20.0% | 0.0% |
|
ACRS
Aclaris Therapeutics, Inc.
Peer
|
-86.7% | -75.9% | +45.0% | +70.6% | +16.4% | -10.6% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
|
ABSI
Absci Corporation
Peer
|
-88.2% | -5.2% | -49.0% | -13.0% | -23.9% | -5.4% |
|
AQST
Aquestive Therapeutics, Inc.
Peer
|
-42.6% | +262.8% | +3.5% | -21.9% | -45.7% | -2.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
8.0
PEG Ratio
N/A
P/B Ratio
8.66
P/S Ratio
1.6
EV/Revenue
1.75
EV/EBITDA
12.2
Market Cap
$360.9M
Profitability
Profit margins and return metrics
Profit Margin
-7.07%
Operating Margin
7.57%
Gross Margin
83.32%
ROE
N/A
ROA
4.8%
Growth
Revenue and earnings growth rates
Revenue Growth
+57.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
4.78
High debt
Current Ratio
1.94
Good
Quick Ratio
1.74
Excellent
Cash/Share
$0.63
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-12
$N/A
2025-11-10
$N/A
+100.0% surprise
2025-08-07
$N/A
+100.0% surprise
2025-05-08
$0.02
+161.8% surprise
Healthcare Sector Comparison
Comparing AKBA against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Profit Margin
-7.07%
This Stock
vs
-20.8%
Sector Avg
-66.0%
(Weaker)
Debt to Equity
4.78
This Stock
vs
2.68
Sector Avg
+78.5%
(Higher)
Revenue Growth
57.0%
This Stock
vs
61.93%
Sector Avg
-8.0%
(Slower)
Current Ratio
1.94
This Stock
vs
3.47
Sector Avg
-44.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
NEUTRAL | $360.9M | - | -% | -7.1% | $1.36 | |
|
ACRS
Aclaris Therapeutics, Inc.
|
BEARISH | $345.62M | - | -113.2% | -% | $3.19 | |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | |
|
ABSI
Absci Corporation
|
BEARISH | $383.45M | - | -55.7% | -% | $2.55 | |
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $395.29M | - | -% | -158.9% | $3.24 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
5 analysts
BTIG
2025-12-02
Buy
Buy
HC Wainwright & Co.
2025-12-02
Buy
Buy
HC Wainwright & Co.
2025-10-30
Buy
Buy
BTIG
2025-10-29
Buy
Buy
Past News Coverage
Recent headlines mentioning AKBA from our newsroom.
Newest → oldest
No matching news yet.